Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025
Vericel (NASDAQ:VCEL), a leader in advanced therapies for sports medicine and severe burn care markets, has scheduled its first-quarter 2025 financial results announcement for May 8, 2025. The company will host a conference call and webcast at 8:30 a.m. ET to discuss financial results and business highlights.
Investors can access the live webcast through Vericel's Investor Relations website. Call participants can dial (800) 715-9871 domestically or (646) 307-1963 internationally. Presentation slides will be available on the webcast and investor relations section. A replay will remain accessible on the company website until May 8, 2026.
Vericel (NASDAQ:VCEL), leader nelle terapie avanzate per la medicina sportiva e il trattamento di gravi ustioni, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 8 maggio 2025. L'azienda terrà una conference call e una diretta webcast alle 8:30 ET per discutere i risultati finanziari e i principali sviluppi aziendali.
Gli investitori potranno accedere alla diretta webcast tramite il sito web delle Relazioni con gli Investitori di Vericel. I partecipanti alla chiamata potranno chiamare il numero (800) 715-9871 per chiamate nazionali o (646) 307-1963 per chiamate internazionali. Le slide della presentazione saranno disponibili durante la webcast e nella sezione relazioni con gli investitori. La registrazione resterà accessibile sul sito aziendale fino all'8 maggio 2026.
Vericel (NASDAQ:VCEL), líder en terapias avanzadas para medicina deportiva y cuidado de quemaduras graves, ha programado el anuncio de resultados financieros del primer trimestre de 2025 para el 8 de mayo de 2025. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 8:30 a.m. ET para discutir los resultados financieros y los aspectos destacados del negocio.
Los inversores pueden acceder a la transmisión en vivo a través del sitio web de Relaciones con Inversores de Vericel. Los participantes en la llamada pueden marcar (800) 715-9871 a nivel nacional o (646) 307-1963 internacionalmente. Las diapositivas de la presentación estarán disponibles durante la transmisión y en la sección de relaciones con inversores. La repetición estará disponible en el sitio web de la empresa hasta el 8 de mayo de 2026.
Vericel (NASDAQ:VCEL)는 스포츠 의학 및 중증 화상 치료 시장을 선도하는 기업으로, 2025년 1분기 재무 결과 발표를 2025년 5월 8일로 예정했습니다. 회사는 오전 8시 30분(동부시간)에 재무 결과와 주요 사업 내용을 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다.
투자자들은 Vericel 투자자 관계 웹사이트를 통해 라이브 웹캐스트에 접속할 수 있습니다. 전화 참가자는 국내에서 (800) 715-9871, 해외에서는 (646) 307-1963으로 전화할 수 있습니다. 발표 자료는 웹캐스트와 투자자 관계 섹션에서 제공되며, 녹화 방송은 2026년 5월 8일까지 회사 웹사이트에서 다시 볼 수 있습니다.
Vericel (NASDAQ:VCEL), leader dans les thérapies avancées pour la médecine du sport et les soins aux brûlures sévères, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 8 mai 2025. La société organisera une conférence téléphonique et une webdiffusion à 8h30 ET pour discuter des résultats financiers et des faits marquants de l'entreprise.
Les investisseurs pourront accéder à la webdiffusion en direct via le site des Relations Investisseurs de Vericel. Les participants à l'appel peuvent composer le (800) 715-9871 aux États-Unis ou le (646) 307-1963 à l'international. Les diapositives de la présentation seront disponibles lors de la webdiffusion et dans la section relations investisseurs. Un replay restera accessible sur le site de la société jusqu'au 8 mai 2026.
Vericel (NASDAQ:VCEL), ein führendes Unternehmen für fortschrittliche Therapien im Bereich Sportmedizin und Behandlung schwerer Verbrennungen, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 8. Mai 2025 geplant. Das Unternehmen wird um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse und wichtige Geschäftshighlights zu besprechen.
Investoren können den Live-Webcast über die Investor-Relations-Website von Vericel verfolgen. Teilnehmer der Telefonkonferenz können innerhalb der USA die Nummer (800) 715-9871 oder international (646) 307-1963 wählen. Die Präsentationsfolien werden während des Webcasts und im Investor-Relations-Bereich verfügbar sein. Eine Aufzeichnung bleibt auf der Unternehmenswebsite bis zum 8. Mai 2026 zugänglich.
- None.
- None.
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time to register and download the required audio software, if necessary. Presentation slides for the conference call will be available on the webcast and on the Investor Relations section of the Vericel website.
To participate by telephone, please dial (800) 715-9871 or (646) 307-1963 if connecting from outside the U.S. When connected, please reference Vericel Corporation first-quarter 2025 earnings call to the operator.
A replay of the webcast will be available on the Vericel website until May 8, 2026.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
When will Vericel (VCEL) release Q1 2025 earnings?
How can investors join Vericel's Q1 2025 earnings call?
How long will Vericel's Q1 2025 earnings call replay be available?
What markets does Vericel (VCEL) operate in?
